DCE-MRI shows treatment response for triple-negative breast cancer

Dynamic contrast-enhanced MRI (DCE-MRI) performs well in predicting early response to immunochemotherapy in women with triple-negative breast cancer, according to a study presented December 6 at the San Antonio Breast Cancer Symposium. Tumor volume reduction shown on DCE-MRI early into neoadjuvant immunochemotherapy regimens can predict treatment response in these women, said Gaiane Rauch from the University of Texas MD Anderson Cancer Center in Houston in her presentation. “Higher accuracy of prediction was seen after four cycles of treatment than after two cycles of neoadjuvant immunochemotherapy,” Rauch said. There remains a need for noninvasive biomarkers for response prediction of neoadjuvant immunochemotherapy in triple-negative breast cancer. Rauch said such markers can guide the least toxic and most effective treatment regimens. Neoadjuvant immunotherapy combined with neoadjuvant chemotherapy has recently become available for treating patients with triple-negative breast cancer, owing to increased rates of pathologic complete response. Previous studies have explored the potential of DCE-MRI to help predict treatment response in breast cancer patients. These include using ultrafast protocols and also AI assistance, demonstrating the modality’s promise in breast imaging. Rauch and colleagues evaluated whether DCE-MRI tumor volume changes that are measured early during immunochemotherapy could predict treatment response. They calculated tumor volume reductio...
Source: AuntMinnie.com Headlines - Category: Radiology Authors: Tags: Breast Source Type: news